INTRODUCTION
Renal tumors are being detected at increasing rates due to the widespread use of modern imaging techniques (1). Typically, these tumors are found incidentally and tend to be small with lower stage yielding better survival outcomes than tumors diagnosed in symptomatic patients (2). Nephron-sparing surgery has gained acceptance as an alternative to radical nephrectomy for treatment of renal tumors less than 4centimetres in diameter (3, 4) . At the same time, use of laparoscopy has resulted in decreased morbidity for patients undergoing renal extirpative surgery. Laparoscopic partial nephrectomy is a viable option in appropriately selected individuals (5). However, hemostasis following tumor excision remains an ongoing challenge. In an effort to optimise hemostasis in nephron-sparing minimally invasive surgery, as well as to further decrease the invasiveness of renal ablative surgery through the use of percutaneous techniques, ablative techniques such as Cryoablation, Radiofrequency Ablation (RFA), and High Intensity Focused Ultrasound (HIFU) have been introduced. Furthermore, patients who are poor surgical candidates and those with hereditary based renal tumors who are at risk of multiple renal operations would benefit from a less invasive treatment modality by avoiding surgical morbidity and potentially better preserving renal function. The following will review various aspects of Renal Cryoablation, Radiofrequency Ablation, High Intensity Focused Ultrasound and sound probe is placed opposite the tumor allowing precise placement of the cryoprobe up to the deep margin of the tumor. Zegel and co-workers (12) found that intraoperative ultrasonography accurately delineated tumor size, cryoprobe placement, and depth of freezing. An echogenic interface was generated by the marked impedance differences at the junction of the normal renal parenchyma and frozen tissue. Shingleton and colleagues (13) demonstrated the feasibility and safety of performing percutaneous renal tumor cryoablation using interventional magnetic resonance imaging (MRI) for monitoring. The advantages include a 3-dimensional view with good soft tissue imaging and it allows imaging distal to the ice ball, which cannot be done by ultrasound secondary to the ice ball acoustic shadowing effect.
Both CT scan and MRI have been used to followup patients after cryoablation (14) The disadvantage of radiologic follow-up, however, is that most cryolesions do not resolve completely (15, 16) .
CLINICAL STUDIES
Cryosurgery on the kidney has been performed using the open approach, laparoscopically and percutaneously.
Open renal cryoablation was performed by Rukstalis and colleagues (17) in 29 patients (median tumor size 2.2 cm). Serious adverse events occurred in 5 patients, with only one event directly related to the procedure. 91 % of patients (mean follow-up 16 months) demonstrated a complete radiographic response with only a residual scar or small, nonenhancing cyst; one patient experienced a biopsy-proven local recurrence. Recently Khorsandi from the same group (18) presented 30 months' (range 10-60) followup data of 17 patients. Follow-up magnetic resonance imaging scans have demonstrated infarction and a reduction of lesion size in 15 of 16 cases. The size of one patient's mass was unchanged after 3 months.
Shingleton and Sewell (13, (19) (20) (21) (22) (23) have reported in several studies on the feasibility and safety of performing percutaneous cryoablation of renal tumors using open MRI. Recently updated data (24) included 65 patients with an average follow-up of 18 months (range 2-30); the 60 surviving patients are without radiographic disease, although 9 of 65 (14 %) required repeat treatment due to incomplete tissue ablation. However, neither postoperative biopsy data nor serial measurements of cryolesions size on CT/ MRI scan were reported. No complications were reported intraoperatively, with one patient requiring a transfusion postoperatively. Harada and co-workers (25) have also evaluated the feasibility of performing percutaneous cryosurgery on 4 patients with renal tumors with local anaesthesia using an open MRI system. Mean tumor size was 4 cm or less; a 2-or 3mm cryoprobe was advanced into the renal mass under real-time MR monitoring. Follow-up physical and dynamic CT examinations were done after 2 and 6 weeks. Cryoablated tumors resolved, and there were no serious complications and no clinically significant changes during the procedure and follow-up study.
Bishoff and associates (26) treated 8 patients with small (average 2 cm) exophytic renal tumors using the laparoscopic approach for biopsy and cryoablation. No intraoperative or postoperative complications occurred, the estimated blood loss was 140 ml, and the mean hospital stay was 3.5 days. At a mean radiological follow-up of 5 months no tumor recurrences or significant changes in the serum creatinine concentration occurred. Levin and colleagues (27) performed laparoscopic cryoablation in 39 patients and reported one patient who underwent renal biopsy at 9 months after the procedure which revealed renal cell carcinoma. Sung et al. (28) reported the intermediate follow-up results of laparoscopic renal cryoablation in 50 patients (34 tumors) with a mean tumor size of 2.1 cm. Cryoablation was performed by either the retroperitoneal (n =38) or the transperitoneal (n =12) laparoscopic approach using real-time ultrasound monitoring. The mean surgical time was 2.6 hours, cryoablation time 20.5 minutes, and blood loss 50.6 ml. For a mean intraoperative ultrasonic tumor size of 2.1 cm, the mean cryolesion size was 3.5 cm. Sequential MRI demonstrated a gradual contraction in the mean diameter of the cryolesions with complete resolution in 9 patients with 2-year-follow up. Of 31 patients who underwent CT guided biopsy at 3-6 months', 30 had negative biopsies. One patient had a 1.3 cm heterogeneous enhancing nodule on 18 month MRI and underwent a nephrectomy based on a positive needle biopsy.
Gill et al. (14) reported of laparoscopic cryoablated lesions (32 patients) with a maximum tumor size of 4 cm. Average follow-up was 16 months (range 7-23) with no recurrence. 23 patients underwent post-procedure biopsies of the residual masses, which were all negative. Lee and colleagues (29) reported on 20 patients with small renal masses (1.4 to 4.5 cm) treated with retroperitoneal laparoscopic renal cryoablation. Renal biopsies revealed renal cell carcinoma in 11 of the 20 patients. Of these 11 patients, none had evidence of recurrent disease at last follow-up, and follow-up scans showed no enhancement of any lesions. Of the 8 patients with followup of 2 years or greater, 4 had complete resolution of the renal lesions. The remainder had lesions that were reduced and stable in size. Complications included surgical re-exploration to evaluate pancreatic injury in 1 patient and failure to ablate a lesion in another.
A concern with cryoablation is bleeding at the probe site and from cracks in the parenchyma during thawing. Nakada (30) and associates noted in an animal study a crack in the renal parenchyma of one kidney during the thaw phase; at harvest the animal was found to have an intraperitoneal haemorrhage. Rukstalis and co-authors (17) routinely packed the probe site with microfibrillar collagen haemostat and applied pressure for 2-3 minutes as well as they used the argon beam coagulation as necessary to control bleeding. The destructive effects of cryoablation are not limited to the kidney; adjacent organs must be protected from contact with the ice ball. Ureteropelvic junction stricture (9), complete bowel obstruction (31) and pancreatic injury have been described. The results of cryolesion involvement with the collecting system are unclear (32) . No systemic adverse effects have been noted after renal cryotherapy.
RADIOFREQUENCY ABLATION

MECHANISM
The mechanism of radiofrequency ablation is heatbased tissue destruction using alternating electrical current at very high frequency (over 400.000 Hz) delivered through a probe inserted into the target tissue. Grounding electrode pads are applied to the patient skin surface to complete the electric current to the RF generator that powers the electrode. The current creates molecular friction in the tissue resulting in local production of heat, denaturation of cellular protein, and cell membrane disintegration. The necessary temperature for tissue thermal destruction is about 70°C to 100°C.
Two basic types of systems are applied: presence or absence of saline perfusion (dry versus wet), and the endpoint of treatment (tissue temperature versus impedance). Temperature-based RF systems are capable of sensing the rise in tissue temperature around the probe, as the tissue around the probe begins to desiccate, and they feed back to the generator to alter the delivery of current as appropriate to heat tissue to the desired target temperature. However, temperature at the electrode tip may not accurately reflect tissue temperature. Impedance-based systems are capable of sensing the rise in tissue impedance (essentially the resistance to flow of electrical current) as the tissue around the probes begins to desiccate, and they feed back to the generator to alter the delivery of current accordingly. A disadvantage of these systems is that tissue impedance varies with the composition of the treated organs and that temperature may not be sufficient to produce coagulative necrosis. Application of RF energy through a dry probe causes a rapid increase in temperature surrounding the probe, leading to tissue desiccation and charring which increases the tissue impedance, interfering with energy transfer through the tissue and limiting the size of the radiofrequency induced lesion. To counter this effect, electrodes may be cooled with saline infused into the treatment tip, decreasing tissue desiccation and allowing treatment of larger tumor volumes. Saline may be infused directly into the tissue parenchyma (wet RFA) prior to and during delivery of energy, allowing better electrical conduction away from the electrode and similarly preventing increased tissue impedance (33) .
Probes can be positioned under CT or ultrasoundguidance. However, their use is limited to monitoring needle placement at the initiation of the ablation. Gas bubbles produced during heating hinder visualisation. Unfortunately, real-time imaging of RF ablations as they are created is not possible with current technology. This is an active area of ongoing research. At least two 10-minute treatments per tumor are performed. Zlotta et al. (34) first reported in 1997 a case of RFA of a small tumor 1 week prior to a radical nephrectomy. They described complete cellular necrosis of the tumor within the radiofrequency lesion. Matlaga and co-workers (35) performed RFA in 10 renal cell carcinomas during open or partial nephrectomy. Mean tumor size was 3.2 cm (1.4 to 8.0 cm). Tumor ablation was complete in 8 of 10 tumors (assessed by NADH staining) with a mean treatment margin of 6.75 mm. Of the two tumors that were not completely ablated, neither reached a temperature greater than 70˚C, and one of the tumors was 8 cm in diameter. Michaels and associates (36) treated 20 tumors (2.4 cm; range 1.5-3.5 cm) in 15 patients just prior to partial nephrectomy. While all tumors grossly appeared completely treated, histological analysis revealed viable tumor cells in all specimens. Five specimens were also stained for NADH activity, revealing positive staining in four of five tumors. In this series of 20 tumors, complications included a single thermal injury to the renal pelvis resulting in ureteropelvic junction obstruction and two single delayed calyceal leaks which resolved with stent placement. Rendon et al. (37) evaluated 11 tumors (mean size 2.4 cm) at nephrectomy immediately after RFA and 1 week following percutaneous RFA. Four of five tumors in the immediate nephrectomy group and three of 6 in the delayed nephrectomy group showed residual viable tumor in about 5% of the tumor volume. Overall, residual viable tumor was noted in 7 of 11 tumors. Complications occurred in 1 patient who sustained a hepatic hematoma, biliary fistula and pneumonia. The findings of the latter 2 studies call into question the adequacy of radiofrequency destruction of tumor cells.
The initial case of percutaneous RFA as a sole treatment for a renal tumor was reported in 1999 by McGovern et al. (38) . Three months after treatment, radiographic follow up (CT) showed no evidence of enhancement. Gervais and colleagues (39) percutaneously ablated 42 biopsy proven RCC in 34 patients under CT or ultrasound guidance using intravenous sedation. All 29 exophytic tumors (mean size 3.2 cm; size range 1.1-5.0 cm) were completely ablated, as were two intraparenchymal tumors. The remaining 11 tumors had a component in the renal sinus. For large (> 3.0 cm) tumors, presence of a tumor component in the renal sinus was a significant negative predictor of technical success; only five of these 11 tumors were completely treated, compared with 11 of 11 tumors without a renal sinus component. Four complications occurred in a total of 54 ablation sessions: one minor hemorrhage, two major hemorrhages, and one ureteral stricture. Pavlovich and coworkers (40) treated 24 tumors in 21 patients with von-Hippel-Lindau syndrome using CT-or ultrasound-guided percutaneous RF under general anaesthesia or sedation. Mean tumor size was 2.4 cm (1.5-3.0 cm). Two-months follow up showed in 79 % of the tumors no contrast enhancement and tumor size decreased to 2.0 cm. The authors reported that in 4 of the 5 persistently enhancing tumors, four did not reach the target temperature (70°C) during treatment. De Baere (41) treated 5 tumors (biopsy-proven RCC, size < 4 cm) in five patients percutaneously under ultrasound or CT guidance. A total of 6 treatments were required. At mean 9-months follow-up all tumors failed to enhance on subsequent CT. Only one complication occurred, a small subcapsular hematoma. Su 
HIGH INTENSITY FOCUSED ULTRASOUND MECHANISM
Radiofrequency and cryoablation require the energy source directly introduced into the tumor by open surgery, laparoscopy or percutaneous application. In contrast, HIFU is able to perform entirely extracorporeal tissue ablation and has therefore the potential to be the least invasive of the tumorablative techniques. Ultrasound waves are generated by high frequency (0.5 to 10 MHz) vibration of a piezoelectric or piezoceramic transducer. They are focused by spherical arrangement, acoustic lens or parabolic reflectors into a small, discrete region, the focal point. As ultrasound energy is only concentrated in that zone, tissue outside of the focal zone is theoretically not heated.
Ultrasound is coupled by degassed water between the source and patient's skin. Because of the comparable acoustic properties of water and tissue, the sound waves should penetrate the skin and further precursory tissue with only slight absorption and reflection. The power density of the converging ultrasound increases as it approaches the focal point. Tis-sue is rapidly heated to temperatures between 65°and 100°C, causing irreversible cell damage and thermal coagulative necrosis. The action of focused ultrasound on tissue results in thermal and nonthermal effects (cavitations, acoustic streaming, oscillatory motion). Evidence also exists that HIFU injures blood vessels less than 2 cm of the focal zone, inducing a secondary ischemic necrosis of target tissue (46) (47) (48) (49) (50) (51) (52) .
The focal region is a cigar-shaped 3-dimensional zone with its long axis perpendicular to the axis of wave propagation. The dimensions of the focal zone are in the order of 10 to 50 mm in length and 1 to 5mm in diameter. A larger volume of tissue can be ablated by sequentially shifting the focal zone by incremental movements of the transducer combined with adjustment of the focal length. The extent of tissue ablation is approximately that of the physical focal zone, but it can be controlled within a limited range by power and duration of the ultrasound pulses (53) . By scanning the target using multiple pulses, larger areas of tissue can be ablated.
Generally, the components of a HIFU system include a transducer to generate and focus ultrasound waves; an imaging device, usually a standard imaging ultrasound probe that can be placed in-line with the HIFU transducer to monitor the treatment under real-time conditions; a coupling device such as a water bath or water cushion to provide an interface for transmission of ultrasound energy from transducer to patient; a housing or gantry for the HIFU device; and a central computing unit from which the operator can control treatment parameters. These control parameters are power output, number of pulses, pulse duration, duration between the pulses, focal length and treatment volume.
HIFU treatments of kidney tissue can be monitored under real-time conditions by standard imaging ultrasound probes placed in line with the therapeutic HIFU transducer. However, a limitation of HIFU is the difficulty in imaging lesions for precise targeting of tissue destruction. Several groups (54-56) have similarly described the limitations of ultrasound in demonstrating detectable tissue changes during or following the creation of lesions. Additional imaging modalities, such as duplex-doppler, CT and MRI, applied in an online thermometry system, are therefore necessary to target the tumour precisely and to monitor the ablation effect online. These new techniques are still under development and investigation.
RESEARCH AND CLINICAL STUDIES
For 50 years patients have been treated with HIFU for various indications, focusing on the brain (57), eye (58) , prostate (benign prostate hyperplasia and cancer; (59), (60)), liver (61) and bladder (62) . Thus far, clinical HIFU for treatment of renal tumors has only been experimental in nature.
In 1992, Chapelon et al. (63) studied the effects of HIFU on rat and canine kidneys (no tumour treatment), and demonstrated lesions consistent with coagulative necrosis or cavitation, depending on the duration and intensity of ultrasound. They were able to create precise tissue lesions; lesion size could be varied depending on the acoustic intensity and the number of firings. In 1996, Adams and colleagues (54) treated implanted VX-2 tumors in rabbit kidneys with the Sonablate transrectal system through surgical exposure as well as transcutaneously. While direct application yielded well-defined areas of tumor ablation, only 7 of 9 tumors were able to be targeted transcutaneously. Four of the 9 rabbits suffered significant skin burns, but there were no injuries to adjacent organs. Watkin and associates (55) reported poor ability to target renal tissue in pigs while using HIFU transcutaneously; only 67 % of total shots fired were detected in the target area. In a large animal model, Paterson et al. (64) tested a HIFU probe for laparoscopic tissue ablation in the kidney. Pathological examination at 14 days revealed reproducible, homogenous and complete tissue necrosis throughout the whole volume of the lesion, with sharp demarcation from adjacent normal tissue.
When treating healthy kidneys of 8 patients with extracorporeally applied HIFU in a phase 1 study, Vallancien et al. (65) did not observe any significant changes in usual laboratory parameters, except for a transient increase in creatine phosphokinase after a long pulse. Side effects included skin burns. Köhrmann et al. (66) applied HIFU to healthy kidney tissue of 24 patients immediately before nephrectomy. In 19 out of the 24 cases, hemorrhage or necrosis was detected macroscopically. Histologically, interstitial hemorrhages and fibre rupture, as well as collagen fiber shrinkage with eosinophilia, were detected in the focal area.
In a phase 2 study, Vallancien et al. (65) treated four patients with T 2 -T 3 renal tumors with HIFU 2, 6, 8 and 15 days before undergoing nephrectomy. Histological examination of the treated kidneys revealed a coagulation necrosis in the targeted tumor area. In two cases a small edema formed in the perirenal fat tissue during surgery. No subcapsular or perirenal hematomas were noted. The muscle wall (lumbar incision) was normal in all cases, and there were no lesions of adjacent organs (colon, inferior vena cava, duodenum, ureter and renal pelvis). During operations done on day 2 or 3, a clearly demarcated necrotic area was detected corresponding to the selected volume. No adverse systemic effects were observed. Two patients had localized first-degree and third-degree skin burns.
Köhrmann et al. (67) reported on a patient with 3 renal tumors who underwent HIFU in three sessions under general or sedation anesthesia and who was followed by clinical examinations and MRI for 6months. After HIFU-treatment, MRI indicated necrosis in the two tumors of the lower pole of the kidney within 17 and 48 days. The necrotic area in these two tumors shrunk thereafter within 6 months (size 2.3 to 0.8 cm and 1.4 to 1.1 cm). Unfortunately, one tumor in the upper pole (size 2.8. cm) was inadequately treated because of absorption of ultrasound energy by interposed ribs. During one session a skin burn of grade 2 occurred.
HIFU is a relatively safe technique. No worsening of renal function in association with the procedure has been reported. Potential risks include hemorrhage, thrombosis and hematomas of the kidney and the tissue through which the waves pass. Complications of HIFU in preclinical studies include incomplete ablation, requiring multiple treatments to ablate the renal lesion completely. Chapelon et al. (63) studied the effects of extracorporeal HIFU (1 MHz transducer) on canine kidneys and reported lesions in 10 out of 16 treated animals (63 %). However, in 13 out of 16 dogs (81 %) abdominal organ lesions occurred (spleen, colon, lung, pancreas). This finding was believed to be due to misfocussing on the target organ. Some improvement was achieved using an ultrasound bidimensional scanner.
As described above, skin burns are common side effects (67) . They occur because of absorption of ultrasound energy at interfaces between two materials that have different attenuation properties. Soft tissues and water have similar attenuation values so ultrasound waves propagate well, with minimal absorption, through these. The greatest clinically relevant attenuation occurs at the level of skin; thus, enough energy can be absorbed by skin over the treatment site to result in 2nd-and 3rd -degree burns. Taking Köhrmann's studies together, three cases of skin burns of grade 3 were observed in 29 treated patients (68) .
INDICATIONS AND LIMITATIONS
The use of Cryoablation, Radiofrequency Ablation and High Intensity Focused Ultrasound for renal tumors is considered investigational. Five-year follow up data are missing. It is primarily useful for treating such lesions in patients with co-morbidities that preclude a major surgical procedure such as partial open or laparoscopic nephrectomy.
Limited data exist on the precise anatomical characteristics that are amenable to ablative techniques (lesion size, location within the kidney, proximity to the collecting system and the renal hilum). Within this investigational area, Cryoablation and RFA are indicated as a treatment for exophytic renal masses less than 4 centimeters in greatest dimension. Laterally-or posteriorly-situated tumors are more amenable to treatment via image-guided percutaneous therapy because of thermal injury to adjacent organs. Medial or anterior lesions are better treated laparoscopically. Actually, no substantial clinical experience with HIFU for renal tumor ablation exists. It is yet unclear what size or location of tumor will be amenable to this form of therapy. From our experience, the majority of candidates are those with small (< 2cm), dorsal and lateral exophytic lesions that are located away from the collecting system.
General contraindications for all 3 techniques are coagulopathy, a completely intrarenal centrally located tumor near the renal sinus or hilum, as injury to the collecting system may result, and significant surgical adhesions for the laparoscopic approach.
Precise pathological diagnosis of the renal lesions (benign or malignant) is critical for determining appropriate clinical and radiological follow-up. Renal biopsy prior to the treatment can be fraught with inaccuracies. In a prospective analysis of 100 renal lesions, Dechet et al. (69) reported non diagnostic rate for CT and needle biopsy of 20 % and 31 %, respectively, and a specificity for both of 20 %. According to this study, accurate preoperative pathological diagnosis using needle biopsy is critical in order to determine long term efficacy of these new technologies.
MISCELLANEOUS TECHNIQUES MICROWAVE THERMOTHERAPY
Tissue absorption of microwaves (30-3.000 MHz) results in increased temperature through production of kinetic energy and heat causing a coagulative necrosis. The probes are placed directly into the target tissue. For the treatment of kidney tumors, only few experimental data exist (70) .
INTERSTITIAL LASER THERMOABLATION
De Jode (71) and colleagues treated kidney tumors in three patients using MRI guided interstitial laser thermoablation. Laser energy (Neodymium-YAG) source was percutaneously delivered to the tumors under real-time MRI guidance. Follow-up confirmed necrosis in the target tissue. However, one patient showed area of enhancement consistent with viable tumor. Additional investigation is needed to determine the ultimate use of lasers in tissue ablation.
INTRACAVITARY PHOTON RADIATION
Using radiation as the energy source, this technology also uses the basic mode of thermotherapy to ablate tissue. The capability of intracavitary photon radiation energy in ablation normal renal parenchyma was demonstrated in an experimental study. Peripheral and central lesions were created in 12 canine kidneys, showing sharply demarcated coagulation necrosis in histology (72) . To date there are no clinical trials existing, where renal tumors are ablated.
FERROMAGNETIC RODS
Ferromagnetic rods can generate an electrical current when placed in a radiofrequency magnetic field. The temperature of the tissue near the rods increases as it is exposed to the electrical current. An advantage of this technology is the ability to reactivate the rods by putting the patient back into the magnetic field as often as needed to treat recurrent lesions in the area of the rod placement. Up to date, for kidney application only experimental data exist (73) . Ferromagnetic rods are in the earliest stages of investigation for urinary malignancies.
CONCLUSIONS
Open partial nephrectomy with its excellent 5-year and 10-year oncologic follow-up data, is still the gold standard therapy for renal tumors less than 4 cm in diameter. All other nephron-sparing alternatives must be compared with these results. The novel ablative technologies can be safely applied to the treatment of small renal tumors, as documented in feasibility studies in animal and human models and a few clinical trials. Lack of histological data on the completeness of tumor destruction and the adequacy of negative surgical margins remains a central critique. Careful long-term clinical and radiological follow-up is important to monitor progress to allow early detection of any local or systemic recurrence. However, prospective clinical trials with sufficient long-term follow-up are missing to document eventual equivalent safety and efficacy of the new methods compared to radical and partial nephrectomy.
Emerging data support the efficacy and reproducibility of renal cryotherapy. Five year follow-up data should be available in the near future. RFA has the potential to further minimize morbidity. However, serious concern remains for this technique regarding the completeness of cancer cell kill and the reliability of intraoperative monitoring. Non-invasive technology advancements such as HIFU have considerable potential for the future.
